

www.eurordis.org

www.eurordis.org

LIST OF MEMBERS IN 2006-2007

Ruby members

Actelion
Baxter
Pharmion
Sigma-Tau USA

Emerald members

Genzyme
GlaxoSmithKline
Helsinn Healthcare
Jerini
Novartis Pharmaceuticals
Sigma-Tau Italy
Swedish Orphan

Sapphire members

Alexion
Aspreva
BioMarin Europe
Boehringer Ingelheim
Celgene International
Dompé farmaceutici
Généthon
Gloucester
Mark Krueger & Associates
Merck Serono
Neurochem
NexGenix
Orfagen
Orphan Europe
PharmaMar
PTC Therapeutics



EURORDIS
Rare Diseases Europe

**THE EURORDIS
ROUND TABLE OF COMPANIES**



The Eurordis Round Table of Companies (ERTC) was set up to establish a long term educational relationship between Eurordis and companies having an interest in orphan drugs, treatments, medical devices, food supplements and health services for people living with rare diseases.

For more information:

www.eurordis.org

(What we do / Round Table of Companies)

or contact:

Fabrizia Bignami, *Therapeutic Development Officer*

fabrizia.bignami@eurordis.org

Tel: +33 1 56 53 52 10



EURORDIS
Rare Diseases Europe

Céphée Com • 04/07
communication

Eurordis - Rare Diseases Europe
www.eurordis.org - eurordis@eurordis.org

Rare Diseases Europe

THE EURORDIS ROUND TABLE OF COMPANIES

MEMBERSHIP BENEFITS

In exchange for the unrestricted funding they provide Eurordis with, ERTC members benefit from:

- Participation in two workshops per year, focussed on issues suggested by companies and patients
- Exchange of views with leaders of the rare disease community: patient representatives, experts, regulators, scientists
- Partnerships with patient groups
- Interaction with other companies
- Mention of members on Eurordis' website and in the annual report

3 LEVELS OF MEMBERSHIP:

- Ruby: 25,000 euros/year
- Emerald: 10,000 euros/year
- Sapphire: 5,000 euros/year

Each ERTC member must sign a Code of Conduct to ensure Eurordis complies with the European Medicines Agency's policy on potential conflicts of interest.

Resources collected by Eurordis through the ERTC enable information, training, and awareness raising activities; they do not fund governance, public and regulatory affairs, and orphan drug activities.



PAST WORKSHOPS

- 5th WORKSHOP: 20 NOVEMBER 2006, PARIS
"Rare disease patient registries: an essential tool in the development of therapies?"
- 4th WORKSHOP: 30 JUNE 2006, BARCELONA
"Common drugs for common needs: the US vs. EU approach to orphan medicinal product development"
- 3rd WORKSHOP: 21ST NOVEMBER 2005, BARCELONA
"Rare disease clinical trials: ensuring fruitful collaborations between sponsors & patient organisations"
- 2nd WORKSHOP: 8TH JULY 2005, PARIS
"New methodologies for clinical trials in small populations"
- 1st WORKSHOP: 17TH DECEMBER 2004, BARCELONA
"Compassionate access programmes for orphan drugs in Europe: from heterogeneity to harmonised practices?"

Concept paper, programme, and list of participants of each workshop can be found on the Eurordis website:

www.eurordis.org